- Home
- CAC vs HUMA Comparison
CAC vs HUMA Comparison
Compare CAC & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- HUMA
- Stock Information
- Founded
- CAC 1875
- HUMA 2004
- Country
- CAC United States
- HUMA United States
- Employees
- CAC N/A
- HUMA N/A
- Industry
- CAC Major Banks
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- CAC Finance
- HUMA Health Care
- Exchange
- CAC Nasdaq
- HUMA Nasdaq
- Market Cap
- CAC N/A
- HUMA 367.6M
- IPO Year
- CAC 1997
- HUMA N/A
- Fundamental
- Price
- CAC $43.10
- HUMA $2.34
- Analyst Decision
- CAC Hold
- HUMA Strong Buy
- Analyst Count
- CAC 3
- HUMA 7
- Target Price
- CAC $47.33
- HUMA $13.00
- AVG Volume (30 Days)
- CAC 62.5K
- HUMA 3.4M
- Earning Date
- CAC 07-29-2025
- HUMA 08-12-2025
- Dividend Yield
- CAC 3.91%
- HUMA N/A
- EPS Growth
- CAC 2.54
- HUMA N/A
- EPS
- CAC 3.09
- HUMA N/A
- Revenue
- CAC $184,324,000.00
- HUMA $517,000.00
- Revenue This Year
- CAC $40.83
- HUMA N/A
- Revenue Next Year
- CAC $5.29
- HUMA $896.45
- P/E Ratio
- CAC $13.92
- HUMA N/A
- Revenue Growth
- CAC 13.26
- HUMA N/A
- 52 Week Low
- CAC $33.83
- HUMA $1.15
- 52 Week High
- CAC $50.07
- HUMA $9.79
- Technical
- Relative Strength Index (RSI)
- CAC 70.29
- HUMA 50.49
- Support Level
- CAC $42.85
- HUMA $2.13
- Resistance Level
- CAC $43.78
- HUMA $2.80
- Average True Range (ATR)
- CAC 0.98
- HUMA 0.18
- MACD
- CAC 0.37
- HUMA 0.01
- Stochastic Oscillator
- CAC 95.06
- HUMA 35.69
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.